1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension

References

• Uemura K., Pisa Z. Trends in cardiovascular disease mortality in industrialised countries since 1950. World Health Statistics Quarterly 1988; 41: 155–168
   PubMedGoogle Scholar
• Burt V. L., Cutler J. A., Higgins M., Horan M. J., Labarthe D., Whelton P., Brown C., Roccella E. J. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys. 1960 to 1991. Hypertension 1995; 26: 60–69
   PubMed Web of Science ®Google Scholar
• Marques-Vidal P., Tuomilehto J. Hypertension awareness treatment and control in the community: is the “rule of halves” still valid?. Journal of Human Hypertension 1997; 11: 213–220
   PubMed Web of Science ®Google Scholar
• Colhoun H. M., Dong W., Poulter N. R. Blood pressure screening, management and control in England: results from the health survey for England 1994. Journal of Hypertension 1998; 16: 747–752
   PubMed Web of Science ®Google Scholar
• Murray C. J. L., Lopez A. D. The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. World Health Organisation: Harvard University Press. 1966
   Google Scholar
• WHO Expert Committee. Hypertension control. WHO Technical Report Series no 862. Geneva: World Health Organisation. 1996
   Google Scholar
• Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in. Eastern Asia. Lancet 1998, (in press)
   Google Scholar
• MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 45,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–1653
   PubMed Web of Science ®Google Scholar
• Kannel W. B., Castelli W. P., McNamara P. M., McKee P. A., Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham Study. New England Journal of Medicine 1972; 287: 781–787
   PubMed Web of Science ®Google Scholar
• Klag M. J., Whelton P. K., Randall B. L., Neaton J. D., Brancati F. L., Ford C. E., Shulman N. B., Stamler J. Blood pressure and end-stage renal disease in men. New England Journal of Medicine 1996; 334: 13–18
   PubMed Web of Science ®Google Scholar
• Rodgers A., Neal B., MacMahon S. The effects of blood pressure lowering in individuals with cerebrovascular disease: an overview of randomised controlled trials. Neurology Reviews International 1997; 2: 12–15
   Google Scholar
• Flack J., Neaton J., Grimm R., Shih J., Cutler J., Ensrud K., MacMahon S. for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation; Journal of the American Heart Association 1995; 92: 2437–2445
   Google Scholar
• Neal B., Clark T., MacMahon S., Rodgers A., Baigent C. Collins o.b.o.t.A.T.A.C. Blood pressure and the risk of recurrent vascular disease. American Journal of Hypertension 1998; 11((4 part 2))25A
   Google Scholar
• Irie K., Yamaguchi T., Minematsu K., Omae T. The J-curve phenomenon in stroke recurrence. Stroke 1993; 24: 1844–1849
   PubMed Web of Science ®Google Scholar
• Cruickshank J. M., Thorp J. M., Zacharias F. J. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 581–583
   PubMed Web of Science ®Google Scholar
• Benetos A., Safar M., Rudnichi A., Smulyan H., Richard J. L., Ducimetieere P., Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–1415
   PubMed Web of Science ®Google Scholar
• Madhavan S., Ooi W. L., Cohen H., Alderman M. H. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401
   PubMed Web of Science ®Google Scholar
• Safar M. E., London G. M., Asmar R., Frohlich E. D. Recent advances on large arteries in hypertension. Hypertension 1998; 32: 156–161
   PubMed Web of Science ®Google Scholar
• Blacher J., Pannier B., Guerin A. P., Marchais S. J., Safar M. E., London G. M. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998; 32: 570–574
   PubMed Web of Science ®Google Scholar
• Safar M. E., Girerd X., Laurent S. Structural changes of large conduit arteries. Journal of Hypertension 1996; 14: 545–555
   PubMed Web of Science ®Google Scholar
• Giannattasio C., Failla M., Mangoni A. A., Scandola L., Fraschnin N.G. M. Evaluation of arterial compliance in humans. Clinical and Experimental Hypertension 1996; 18: 347–362
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Statistics Annual. Geneva: World Health Organization. 1995
   Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 1991; 325: 293–302
   PubMed Web of Science ®Google Scholar
• UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. Journal of Neurology, Neurosurgery, and Psychiatry 1991; 54: 1044–1054
   PubMed Web of Science ®Google Scholar
• The LIPID Study Group. Prevention of mortality and cardiovascular events with pravastatin in 9,014 patients with coronary heart disease and broad range of cholesterol levels. New England Journal of Medicine 1998, (in press)
   Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine 1992; 327: 685–691
   PubMed Web of Science ®Google Scholar
• Wong N. D., Levy D., Kannel W. B. Prognostic significance of the electrocardiogram after Q wave myocardial infarction. The Framingham Study. Circulation; Journal of the American Heart Association 1990; 81: 780–789
   Google Scholar
• MacMahon S., Collins G., Rautaharju P., Cutler J., Neaton J., Prineas R., Crow R., Stamler J. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. American Journal of Cardiology 1989; 63: 202–210, for the Multiple Risk Factor Intervention Trial Research Group.
   PubMed Web of Science ®Google Scholar
• Levy D., Garrison R., Savage D., Kannel W., Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine 1990; 322: 1561–1566
   PubMed Web of Science ®Google Scholar
• Salonen J. T., Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arteriosclerosis and Thrombosis 1991; 11: 1245–1249
   PubMed Web of Science ®Google Scholar
• Zanchetti A., Agatiti R. E., Dal P. C., Lernetti G., Magnami B., Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension 1998, 16 Nov(in press) for the VHAS Investigators.
   Web of Science ®Google Scholar
• Shulman N. B., Ford C. E., Hall W. D., Blaufox M. D., Simon D., Longford H. G., Schneider K. A. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension 1989; 13(Suppl I)90–93, on behalf of the Hypertension Detection and Follow-up Program Group.
   Google Scholar
• Samuelsson O., Wilhelmsen L., Elmfeldt D., Pennert K., Wedel H., Wikstrand J., Berglund G. Predictors of cardiovascular morbidity in treated hypertension: Results from the Primary Preventive Trial in Goteborg Sweden. Journal of Hypertension 1985; 3: 167–176
   PubMed Web of Science ®Google Scholar
• US Renal Data System. USRDS 1997 Annual Report. Bethesda, MD. National Institute of Diabetes and Digestive and Kidney Diseases. 1997
   Google Scholar
• Gall M.-A., Borch-Johnsen B., Hougaard P., Nielsen F. S., Parving H.-H. Albuminuria and poor glycecmi control predict mortality in NIDDM. Diabetes 1995; 44: 1303–1309
   PubMed Web of Science ®Google Scholar
• Stamler J., Vaccaro O., Neaton J. D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444, for the Multiple Risk Factor Intervention Trial Research Group.
   PubMed Web of Science ®Google Scholar
• Abbott R. D., Donahue R. P., MacMahon S. W., Reed D. M., Yano K. Diabetes and the risk of stroke: The Honolulu Heart Project. Journal of the American Medical Association 1987; 257: 949–952
   Web of Science ®Google Scholar
• Despres J.-P., Lamarche B., Mauriege P., Cantin B., Dagenais G. R., Moorjani S.P-J. L. Hyperinsulinemia is an independent risk factor for ischemic heart disease. New England Journal of Medicine 1996; 334: 952–957
   PubMed Web of Science ®Google Scholar
• Gerstein H. C., Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347: 949–950
   PubMed Web of Science ®Google Scholar
• Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994; 309: 901–111
   PubMed Web of Science ®Google Scholar
• Law M. R., Wald N. J., Thompson S. G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. British Medical Journal 1994; 308: 367–373
   PubMed Web of Science ®Google Scholar
• Gordon D. J., Probstfield J. L., Garrison R. J., Neaton J. D., Castelli W. P., Knoke J. D., Jacobs D. R., Bangdiwala S., Tyroler H. A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation; Journal of the American Heart Association 1989; 79: 8–15
   Google Scholar
• Rimm E. B., Stampfer M. J., Ciovannucci E., Ascherio A., Spiegelman D., Colditz G. A., Willett W. C. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. American Journal of Epidemiology 1995; 141: 1117–1127
   PubMed Web of Science ®Google Scholar
• Stampfer M. J., Sacks P. M., Salvini S., Willett W. C., Hennekens C. H. A prospective study of cholesterol, apoiipoproteins, and the risk of myocardial infarction. New England Journal of Medicine 1991; 325: 373–381
   PubMed Web of Science ®Google Scholar
• Stern M. P., Haffner S. M. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986; 6: 123–130
   PubMedGoogle Scholar
• Woodward M., Lowe G. D. O., Rumley A., Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. European Heart Journal 1998; 19: 55–62
   PubMed Web of Science ®Google Scholar
• Ernst E., Resch K. L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Annals of Internal Medicine 1993; 118: 956–963
   PubMed Web of Science ®Google Scholar
• Rimm E. R., Klatsky A., Grobbee D., Stampher M. J. Review of moderate alcohol consuption and reduced risk of coronary heart disease: is the effect due to beer wine or spirits?. British Medical Journal 1996; 312: 731–716
   PubMed Web of Science ®Google Scholar
• Thun M. J., Peto R., Lopez A. D., Monaco J. H., Henley S. J.C. W. H., Doll R. Alcohol consumption and mortality among middle-aged and elderly US adults. New England Journal of Medicine 1997; 337: 1705–1714
   PubMed Web of Science ®Google Scholar
• Wannamethee S. G., Shaper A. G. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke 1996; 27: 1033–1039
   PubMed Web of Science ®Google Scholar
• Leon A. S., Myers M. J., Connett J., for the MRFIT Research Group. Leisure time physical activity and the 16-year risks of mortality from coronary heart disease and all-causes in the Multiple Risk Factor Intervention Trial (MRFIT). International Journal of Sports Medicine 1997; 18(Suppl 3)S208–S215
   PubMed Web of Science ®Google Scholar
• Arakawa K. Effect of exercise on hypertension and associated complications. Hypertension Research 1996; 19(Suppl)S87–S91
   Google Scholar
• Grodstein F., Stampfer J. J., Colditz G. A., Willett W. C., Manson J. E., Joffe M., Rosner B., Fuchs C., Hankinson S. E., Hunter D. J., Hennekens C. H., Speizer F. E. Postmenopausal hormone therapy and mortality. New England Journal of Medicine 1997; 336: 1769–1775
   PubMed Web of Science ®Google Scholar
• Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS). Journal of the American Medical Association 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Davey-Smith G., Neaton J. D., Wentworth D., Stamler R., Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: I. White men. American Journal of Public Health 1996; 86: 486–496
   PubMed Web of Science ®Google Scholar
• Whitlock G., MacMahon S., Vander Hoorn S., Davis P., Jackson R., Norton R. Socioeconomic distribution of smoking in a population of 10 529 New Zealanders. New Zealand Medical Journal 1997; 110: 327–330
   PubMed Web of Science ®Google Scholar
• Sheth T., Bosch J., Chen J., Anand S., Nargundkar M., Nair C., Yusuf S. Ethnic differences in Socioeconomic status and mortality. 50th annual meeting of the Canadian Cardiovascular Society. Canadian Journal of Cardiology 1997; 13(Suppl C)89
   Google Scholar
• Tipene-Leach D., Stewart A., Beaglehole R. Coronary heart disease mortality in Auckland Maori and Europeans. New Zealand Medical Journal 1991; 104: 53–57
   Google Scholar
• Lee E. J., Cowan L. D., Welty T. K., Sievers M., Howard W. J., Oopik A., Wang W., Yeh J., Devereux R. B., Rhoades E. R., Fabsitz R. R., Go O., Howard B. V. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45–74 years, 1984–1988. The Strong Heart Study. American Journal of Epidemiology 1998; 147: 995–1008
   PubMed Web of Science ®Google Scholar
• Broderick J., Brott T., Kothari R., Miller R., Khoury J., Pancioli A., Gebel J., Mills D., Minneci L., Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study. Preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998; 29: 415–421
   PubMed Web of Science ®Google Scholar
• Klag M. J., Whelton P. K., Randall B. L., Neaton J. D., Brancati F. L., Stamler J. End-stage renal disease in African-American and white men. Journal of the American Medical Association 1997; 277: 1293–1298
   PubMed Web of Science ®Google Scholar
• Cappuccio F. P. Ethnicity and cardiovascular risk: variations in people of African ancestry and South Asian origin. Journal of Human Hypertension 1997; 11: 571–576
   PubMed Web of Science ®Google Scholar
• Sheth T., Nair C., Nargundkar M., Anand S., Yusuf S. Cardiovascular and cancer mortality among Whites. South Asians, and Chinese in Canada from 1979 to 1993; An analysis of 2.6 million deaths. Canadian Medical Asociation Journal 1998, (in press)
   Google Scholar
• WHO-MONICA Project, Tunstall-Pedoe, Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A. M., Pajak A. Myocardial infarction and coronary deaths in the Worid Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation; Journal of the American Heart Association 1994; 90: 583–612
   Google Scholar
• WHO-MONICA Project, Stegmayr B., Asplund K., Kuulasmaa K., Rajakangas A.-M., Thorvaldsen P., Tuomilehto J. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project. An ecological study of 18 populations. Stroke 1997; 28: 1367–1374
   PubMed Web of Science ®Google Scholar
• Yao C., Wu Z., Wu Y. The changing pattern of cardiovascular diseases in China. Worid Health Statistics Quarterly 1993; 46: 113–118
   PubMedGoogle Scholar
• Collins R., Peto R., MacMahon S., Herbert P., Fiebach N. H., Eberlein K. A., Godwin J., Qizibash N., Taylor J. O., Hennekens C. H. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–839
   PubMed Web of Science ®Google Scholar
• Collins R., MacMahon S. Blood pressure antihypertensive drug treatment and the risks of stroke and of coronary heart disease. British Medical Bulletin 1994; 50: 272–298
   PubMed Web of Science ®Google Scholar
• MacMahon S., Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. Journal of Vascular Medicine and Biology 1993; 4: 265–271
   Google Scholar
• Messerii F. H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderiey? A systematic review. Journal of the American Medical Association 1998; 279: 1903–1907
   Web of Science ®Google Scholar
• Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal 1985; 291: 97–104
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal 1992; 304: 405–412
   PubMed Web of Science ®Google Scholar
• The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). Journal of Hypertension 1985; 3: 379–392
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L., Berglund G., Elmfeld D., Fitzsimons T., Holzgreve H., Hosie J., Hömkvist P.-E., Pennert K., Tuomilehto J., Wedel H. on behalf of the Heart Attack Primary Prevention in Hypertension Trial Research Group. Beta-blockers versus diuretics in hypertensive men. Main results from the HAPPHY trial. Journal of Hypertension 1987; 5: 561–572
   PubMed Web of Science ®Google Scholar
• Kostis J. B., Davis B. R., Cutler H. G., Berge K. G., Cohen J. D., Lacy C. R., Perry H. M., Blaufox M. U., Wassertheil-Smoller S., Black H. R., Schron E., Berkson D. M., Curb J. D., McFate Smith W., McDonald R., Applegate W. B., for the SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. Journal of the American Medical Association 1997; 278: 212–216
   PubMed Web of Science ®Google Scholar
• Yusuf S., Thomas T., Abbott R. D. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989; 13(suppl I)I74–I79
   Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Journal of the American Medical Association 1991; 265: 3255–3264
   PubMed Web of Science ®Google Scholar
• Staessen J. A., Fagard R., Thijs L., Celis H., Arabidze G. G., Birkenhager W. H., Bulpitt C. J., De Leeuw P. W., Dollery C. T., Fletcher A. E., Forette F., Leonetti G., Nachev C., O'Brien E. T., Rosenfeld J., Rodicio J. L., Tuomilehto J., Zanchetti A. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764
   PubMed Web of Science ®Google Scholar
• Gong L., Zhang W., Zhu Y., Zhu J. 11 collaborating centres in the Shanghai area, Kong D., Page V., Ghadirian P., LeLorier J., Hamet P. Shanghai trial of nifedipine in the eldeny (STONE). Journal of Hypertension 1996; 14: 1237–1245
   PubMed Web of Science ®Google Scholar
• Liu L., Wang J. G., Gong L., Liu G., Staessen J. A., Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension. Journal of Hypertension 1998, (in press)
   Google Scholar
• Hansson L., Lindholm L. H., Niskanen L., Lanke J., Hedner T., Niklason A., Luomannmaki K., Dahlof B., De Faire U., Morlin C., Karlberg B. E., Wester P. O., Bjorck J.-E., CAPPP Study Group. Principal results of the Captopril Prevention Project (CAPPP). Lancet 1998, (in press)
   Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. British Medical Journal 1998; 317: 713–720
   PubMed Web of Science ®Google Scholar
• Hansson L., Zanchetti A., Carruthers S. G., Dahlof B., Elmfeldt D., Menard J., Julius S., Rahn K. H., Wedel H., Westerling S. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 1998; 317: 703–713
   PubMed Web of Science ®Google Scholar
• Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Journal of Hypertension 1997; 15: 105–115
   PubMed Web of Science ®Google Scholar
• Lever A. F., Hole D. J., Gillis C. R., McCallum I. R., McInnes G. T., MacKinnon P. L., Meredith P. A., Murray L. S., Reid J. L., Robertson J. W. K. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 1998; 352: 179–184
   PubMed Web of Science ®Google Scholar
• Forette F., Seux M. C., Thijs L., Staessen J. A. Antihypertensive treatment and prevention of dementia in older patients with isolated systolic hypertension: the Syst-Eur results. Journal of Hypertension 1998; 16(Suppl 2)S22, (abstract 9Z1)
   Google Scholar
• Mancia G., Sega R., Milesi C., Cesana G., Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454–457
   PubMed Web of Science ®Google Scholar
• Tao S., Wu X., Duan X., Fang W., Hao J., Fan D., Wang W., Li Y. Hypertension prevalence and status of awareness treatment and control in china. Chinese Medical Journal 1995; 108: 483–489
   PubMed Web of Science ®Google Scholar
• Isles C. G., Walker L. M., Beevers G. D., Brown I., Cameron H. L, Clarke J., Hawthorne V., Hole D., Lever A. F., Robertson J. W. K., Wapshaw J. A. Mortality in patients of the Glasgow Blood Pressure Clinic. Journal of Hypertension 1986; 4: 141–156
   PubMed Web of Science ®Google Scholar
• Gamble G., MacMahon S., Culpan A., Ciobo C., Whalley G., Sharpe N. Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. Journal of Hypertension 1998; 16: 1389–1395
   PubMed Web of Science ®Google Scholar
• Tang J. L., Armitage J. M., Lancaster T., Silagy C. A., Fowler G. H., Neil H. A. W. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. British Medical Journal 1998; 316: 1213–1220
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389
   PubMed Web of Science ®Google Scholar
• Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. for the West of Scotland Coronary Prevention Study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolenva. New England Journal of Medicine 1995; 333(20)1301–1307
   PubMed Web of Science ®Google Scholar
• Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M. O., Wun C. C., Davis B. R., Braunwald E. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996; 335: 1001–1009
   PubMed Web of Science ®Google Scholar
• Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Stein E. A., Kruyer W., Gotto A. M. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association 1998; 279: 1615–1622
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 1994; 308: 81–106
   PubMed Web of Science ®Google Scholar
• Hennekens C. H., Buring J. E., Peto R. Antioxidant vitamins—benefits no yet proved. New England Journal of Medicine 1994; 330: 1080–1081
   PubMed Web of Science ®Google Scholar
• Mancia G., Parati G., Di Rienzo M., Zanchetti A. Blood pressure variability. Handbook of Hypertension. Pathophysiology of hypertension, A. Zanchetti, G. Mancia. Elsevier Science. 1997; Vol. 17: 117–169
   Google Scholar
• Laragh J. H., Brenner B. M. Hypertension: Pathophysiology, Diagnosis and Management. chapters 112–1152nd ed. Raven Press, New York 1995; 1897–1952
   Google Scholar
• Swales J. D. Textbook of Hypertension. Blackwell, London 1994; 989–1008, Chapter 55
   Google Scholar
• Ohkubo T., Imai Y., Tsuji I., Nagai K., Kato J., Kikuchi N., Nishiyama A., Aihara A., Sekino M., Kikuya M., Ito S., Satoh H., Hisamichi S. Home blood pressure measurement has a stronger predictive power for mortality than dose screening blood pressure measurement: a population-based observation in Ohasama Japan. Journal of Hypertension 1998; 16: 971–975
   PubMed Web of Science ®Google Scholar
• Mancia G., Di Rienzo M., Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension 1993; 21: 510–524
   PubMed Web of Science ®Google Scholar
• Mancia G., Sega R., Bravi D., De Vito G., Valagussa F., Cesana G., Zanchetti A. Ambulatory blood pressure normality: results from the PAMELA Study. Journal of Hypertension 1995; 13: 1377–1390
   PubMed Web of Science ®Google Scholar
• Pyorala K., Graham I., Mancia G., Poole-Wilson P., Wood D. on behalf of the Task Force., Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. European Heart Journal 1998
   Google Scholar
• Zanchetti A., Bond M. G., Henning M., Neiss A., Mancia G., Dal Palu C., Hansson L., Magnani B., Rahn K.-H., Reid J., Rodicio J., Safar M., Eckes L., Ravinetto R. on behalf of the ELSA Investigators. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. Journal of Hypertension 1998; 16: 949–961
   PubMed Web of Science ®Google Scholar
• Fagard R. H., Staessen J. A., Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension 1997; 29: 22–29
   PubMed Web of Science ®Google Scholar
• Perloff D., Sokolow M., Cowan R., Juster R. Prognostic value of ambulator/blood pressure measurement. Journal of Hypertension 1989; 7(Suppl 3)S3–S10
   Google Scholar
• Verdecchia P., Porcellati C., Shillaci G., Borgioni C., Ciucci A., Battistelli M. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801
   PubMed Web of Science ®Google Scholar
• Redon J., Campos C., Narciso M.L.J. L. R., Pasquale J. M., Ruilope L. M. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712–718
   PubMed Web of Science ®Google Scholar
• Ohkubo T., Imai Y., Tsuji I., Nagai K., Ito S., Satoh H., Hisamichi S. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: Ohasama study. Hypertension 1998; 32: 255–259
   PubMed Web of Science ®Google Scholar
• Mancia G., Zanchetti A., Agebiti-Rosei E., Benemio G., De Cesaris R., Fogari R., Pessino A., Porcellati C., Salvetti A., Trimarco B. for the SAMPLE Study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation; Journal of the American Heart Association 1997; 95: 1464–1470
   Google Scholar
• Mancia G., Omboni S., Parati G. Assessment of antihypertensive treatment by ambulatory blood pressure. Journal of Hypertension 1997; 15(Suppl 2)S43–S50
   Google Scholar
• Pickering T. G., James G. D., Boddie C., Harshfield G. A., Blank S. How common is white coat hypertension?. Journal of the American Medical Association 1988; 259: 225–228
   PubMed Web of Science ®Google Scholar
• Mancia G., Zanchetti A. Editors' comer: white-coat hypertension: misnomers misconceptions and misunderstandings. What should we do next? Journal of Hypertension 1996; 14: 1049–1052
   PubMed Web of Science ®Google Scholar
• Parati G., Ulian L., Santicciu C., Omboni S., Mancia G. Difference between dinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 1998; 31: 1185–1189
   PubMed Web of Science ®Google Scholar
• Mancia G., Parati G., Pomidossi G., Grassi G., Casadei R., Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9: 209–215
   PubMed Web of Science ®Google Scholar
• Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Archives of Internal Medicine 1993; 153: 154–183
   PubMed Web of Science ®Google Scholar
• Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI). Archives of Internal Medicine 1997; 157: 2413–2446
   PubMed Web of Science ®Google Scholar
• The Guidelines Subcommittee of the WHO-ISH Mild Hypertension Liaison Committee. 1993 Guidelines for the Management of Mild Hypertension. Memorandum from a World Health Organization-International Society of Hypertension Meeting. Journal of Hypertension 1993; 11: 905–918
   PubMed Web of Science ®Google Scholar
• Chalmers J., Zanchetti A. Reply to a critique of the 1996 World Health Organisation expert committee report on hypertension. Journal of Hypertension 1997; 15: 684–685
   Web of Science ®Google Scholar
• Lindholm L., Ejlertsson G., Schersten B. High risk of cerebrovascular morbidity in well treated male hypertensives: a retrospective study of 40–59 year old hypertensives in a Swedish primary care district. Acta Medica Scandinavica 1984; 216: 251–259
   PubMed Web of Science ®Google Scholar
• Silagy C., Mant D., Fowler G., Lodge M. Meta-anatysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139–142
   PubMed Web of Science ®Google Scholar
• Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Annals of Epidemiology 1991; 1: 347–362
   PubMedGoogle Scholar
• Reid C. M., Dart A. M., Dwar E. M., Jennings G. L. Interactions between the effects of exercise and weight loss on risk factors cardiovascular haemodynamics and left ventricular structure in overweight subjects. Journal of Hypertension 1994; 12: 291–301
   PubMed Web of Science ®Google Scholar
• Puddey I. B., Parker M., Beiling L. J., Vandongen R., Masarei J. R. L. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992; 20: 533–541
   PubMed Web of Science ®Google Scholar
• Whelton P. K., Appel L. J., Espeland M. A., Applegate W. B., Ettinger W. H., Kostis J. B., Kumanyiaka S., Lacy C. R., Johnson K. C., Folmar S., Cutler J. A. for TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the Elderly (TONE). Journal of the American Medical Association 1998; 279: 839–846
   PubMed Web of Science ®Google Scholar
• Puddey I. B., Beilin L. J., Rakic V. Alcohol hypertension and the cardiovascular system: A critical appraisal. Addiction Biology 1997; 2: 159–170
   PubMed Web of Science ®Google Scholar
• Puddey I. B., Beilin L. J., Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomized controlled trial. Lancet 1987; i: 647–651
   Google Scholar
• Law M. R. Epidemiological evidence on salt and blood pressure. American Journal of Hypertension 1997; 10: 4S–45S
   Google Scholar
• Cutler J. A., Follman D., Alexander P. S. Randomised controlled trials of sodium reduction: An overview. American Journal of Clinical Nutrition 1997; 65(Suppl)643S–651S
   Google Scholar
• Rouse I. L., Armstrong B. K., Beilin L. J. The relationship of blood pressure to diet and lifestyle in two religious populations. Journal of Hypertension 1983; 1: 65–71
   PubMedGoogle Scholar
• Margetts B. M., Beilin L. J., Vandongen R., Armstrong B. K. Vegetarian diet in mild hypertension: A randomized controlled trial. British Medical Journal 1986; 293: 1468–1471
   PubMed Web of Science ®Google Scholar
• Appel L. J., Moore T. J., Obarzanek E., Vollmer W. M., Svetkey L. P., Sacks P. M., Bray G. A., Vogt T. M., Cutler J. A., Whindhauser M. M., Lin P. H., Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. New England Journal of Medicine 1997; 336: 1117–1124
   PubMed Web of Science ®Google Scholar
• Bao D. G., Mori T. A., Burke V., Puddey I. B., Beilin L. J. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension 1998; 32: 710–717
   PubMed Web of Science ®Google Scholar
• Jennings G. L. R. Exercise and blood pressure: walk, run or swim?. Journal of Hypertension 1997
   Google Scholar
• Arakawa K. Antihypertensive mechanism of exercise. Journal of Hypertension 1993; 11: 223–229
   PubMed Web of Science ®Google Scholar
• Fagard R. H. The role of exercise in blood pressure control: supportive evidence. Journal of Hypertension 1995; 13: 1223–1227
   PubMed Web of Science ®Google Scholar
• Puddey I. B., Cox K. Exercise lowers blood pressure—sometimes? Or did Pheidippides have hypertension?. Journal of Hypertension 1995; 13: 1229–1233
   PubMed Web of Science ®Google Scholar
• Beilin L. J. Stress coping lifestyle and hypertension: A paradigm for research prevention and non-pharmacological management of hypertension. Clinical and Experimental Hypertension 1997; 19: 739–752
   PubMed Web of Science ®Google Scholar
• Lindquist T. L., Beilin L. J., Knuiman M. W. Influence of lifestyle coping and job stress on blood pressure in men and women. Hypertension 1997; 29: 1–7
   PubMed Web of Science ®Google Scholar
• Nyklicek I., Vingerhoets J. J. M., Van Heck G. L. Hypertension and objective and self-reported stressor expertise: A review. Journal of Psychosornosis Research 1996; 40: 585–601
   PubMed Web of Science ®Google Scholar
• Pickering T. G., Devereux R. B., James G. D., Gerin W., Landsbergis P., Schnall P. L., Schawartz J. E. Environmental influences on blood pressure and the role of job strain. Journal of Hypertension 1996; 14(Suppl 5)S179–S185
   Google Scholar
• Parati G., Pomidossi G., Albini P., Malaspina D., Mancia G. Relationship of 24 hour blood pressure mean and variability to severity of target organ damage in hypertension. Hypertension 1987; 5: 93–98
   Web of Science ®Google Scholar
• Frattola A., Parati G., Cuspidi G., Albini F., Mancia G. Prognostic value of 24 hour blood pressure variability. Journal of Hypertension 1993; 11: 1133–1137
   PubMed Web of Science ®Google Scholar
• Siscovick D., Raghunathan T., Psaty B., Keopsell T., Wicklund K., Xiphong Lin M., Cobb L., Rantaharju P., Copass M., Wagner E. Diuretic therapy for hypertension and the risk of primary cardiac arrest. New England Journal of Medicine 1994; 330: 1852–1857
   PubMed Web of Science ®Google Scholar
• Hoes A., Grobbee D., Lubsen J., Man in't Veld A., Van der Does E., Hofman A. Diuretics, beta-blockers, and the risk of sudden cardiac death in hypertensive patients. Annals of Internal Medicine 1995; 123: 481–187
   PubMed Web of Science ®Google Scholar
• Doughty R., Rodgers A., Sharpe N., MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. European Heart Journal 1997; 18: 560–565
   PubMed Web of Science ®Google Scholar
• Yasue H., Kugiyama K. Coronary spasm: Japanese View. Coronary Artery Disease 1990; 1: 668–673
   Web of Science ®Google Scholar
• Garg R., Yusuf S. for the Collaborative Group on ACE inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Journal of the American Medical Association 1995; 273: 1450–1456
   PubMed Web of Science ®Google Scholar
• Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. for the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine 1993; 329: 1456–1462
   PubMed Web of Science ®Google Scholar
• Israili Z., Hall W. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Annals of Internal Medicine 1992; 117: 234–242
   PubMed Web of Science ®Google Scholar
• Johnston C. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403–1407
   PubMed Web of Science ®Google Scholar
• Neaton J. D., Grimm R. H., Prineas R. J., Stamter J., Grandits G. A., Elmer P. J., Cutler J. A., Flack J. M., Schoenberger J. A., McDonald R., Lewis C. E., Liebson P. R. for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. Journal of the American Medical Association 1993; 270: 713–724
   PubMed Web of Science ®Google Scholar
• Brown M. A., Whitworth J. A. Pregnancy. Contemporary Issues in Nephrology: Pharmacology and Management of Hypertension, W. M. Bennett, D. A. McCarron. Churchill Livingstone, New York 1994; Vol. 28: 89–116
   Google Scholar
• Cooper R. S., Liao Y., Rotimi C. Is hypertension more severe among US Blacks or is severe hypertension more common?. Annals of Epidemiology 1996; 6: 173–180
   PubMed Web of Science ®Google Scholar
• Bullen C., Tipene-Leach D., Vander Hoom S., Jackson R., Norton R., MacMahon S. Ethnic differences in blood pressure: findings from the Fletcher Challenge-University of Auckland University Heart and Health Study. New Zealand Medical Journal 1996; 109: 395–397
   PubMed Web of Science ®Google Scholar
• World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. Journal of Hypertension 1998; 16: 127–137
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. American Journal of Obstetrics and Gynecology 1990; 163: 1589–1712
   Google Scholar
• Australasian Society for the Study of Hypertension in Pregnancy. Management of hypertension in pregnancy: executive summary. Medical Journal of Australia 1993; 158: 700–702
   PubMed Web of Science ®Google Scholar
• Collins R., Yusuf S., Peto R. Overview of randomised trials of diuretics in pregnancy. British Medical Journal Clinical Research Edition 1985; 290: 17–23
   PubMed Web of Science ®Google Scholar
• CLASP Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnarit women. Lancet 1994; 343: 619–629
   PubMed Web of Science ®Google Scholar
• MacMahon S., Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Journal of Clinical and Experimental Hypertension 1993; 15: 967–978
   PubMed Web of Science ®Google Scholar
• Dahlöf B., Lindeholm L. H., Hansson L., Schersten B., Ekbom T., Wester P. O. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285
   PubMed Web of Science ®Google Scholar
• Staessen J. A., Fagard R., Thijs L., Celis H., Birkenhager W.H.C. J. B., de Leeuw P. W., Fletcher A. E., Babarskiene M.-R., Forette F., Kocemba J., Laks T., Leonetti G., Nachev G., Petrie J. C., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Zanchett A. for the Systolic Hypertension in Europe Trial Investigators. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine 1998; 158: 1681–1691
   PubMed Web of Science ®Google Scholar
• The INDANA (INdividual Data ANalysis of Antihypertensive interventional trials) Project Collaborators, Gueyffier F., Boissel J.-P., Boutitie F., Pocock S., Coope J., Cutler J., Ekbom T., Fagard R., Friedman L., Kerlikowske K., Perry M., Prineas R., Schron E. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. Stroke 1997; 28: 2557–2562
   PubMed Web of Science ®Google Scholar
• PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. Journal of Hypertension 1996; 14(suppl 2)S41–S46
   PubMedGoogle Scholar
• Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases 1985; 27: 335–371
   PubMed Web of Science ®Google Scholar
• Lonn E. M., Yusuf S., Jha P., Montague T. J., Teo K. K., Benedict C. R., Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056–2069
   PubMed Web of Science ®Google Scholar
• The HOPE Study Investigators. The HOPE (Heart Outcome Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12: 127–137
   PubMed Web of Science ®Google Scholar
• Brown M. A., Whitworth J. A. Hypertension in human renal disease. Journal of Hypertension 1992; 10: 701–712
   PubMed Web of Science ®Google Scholar
• Iseki K., Ikemiya Y., Fukiyama K. Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney International 1996; 49(S55)S69–71
   Google Scholar
• Ritz E., Rambausek M., Hasslacher C., Mann J. Pathogenesis of hypertension in renal. American Journal of Nephrology 1989; 9: 85–90
   PubMed Web of Science ®Google Scholar
• Krolewski A. S., Canessa M., Warran J. H., Laffel L. M. B., Christlich A. R., Knowler W. C., Rand L. I. Predisposition to hypertension and susceptibility to renal disease in insulin dependent diabetes mellitus. New England Journal of Medicine 1988; 318: 140–145
   PubMed Web of Science ®Google Scholar
• Bergström J., Alvestrand A., Bucht H., Gutlerrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clinical Nephrology 1986; 25: 1–6
   PubMed Web of Science ®Google Scholar
• Ihle B. U., Whitworth J. A., Shahinfar S., Cnaan A., Kincaid-Smith P. S., Becker G. J. Angiotensin converting enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blind trial. American Journal of Kidney Diseases 1996; 27: 489–495
   PubMed Web of Science ®Google Scholar
• Peterson J. C., Adler S., Bukart J. M., Greene T., Hebert L. A., Hunsicker L. G., King A. J., Klahr S., Massry S. G., Seifter J. L. for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control proteinuria arid the progression of renal disease. Annals of Internal Medicine 1995; 123: 754–762
   PubMed Web of Science ®Google Scholar
• Simonson D. C. Eitology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11: 821–827
   PubMed Web of Science ®Google Scholar
• Epstein M., Sowers J. R. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403–418
   PubMed Web of Science ®Google Scholar
• Reaven G. M., Lithell H., Lansberg L. Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system. New England Journal of Medicine 1996; 334: 374–381
   PubMed Web of Science ®Google Scholar
• Haffner S. M. Insulin and blood pressure: fact or fantasy?. Journal of Clinical Endocrinology and Metabolism 1993; 76: 541–542
   PubMed Web of Science ®Google Scholar
• Grossman E., Messerli F. H. Diabetic and hypertensive heart disease. Annals of Internal Medicine 1996; 125: 304–310
   PubMed Web of Science ®Google Scholar
• Borch-Johnson K., Nissen R., Nerup J. Blood pressure after 40 years of insulin-dependent diabetes. Nephron 1985; 4: 11–12
   Google Scholar
• Mogensen C. E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. British Medical Journal 1982; 285: 685–688
   PubMed Web of Science ®Google Scholar
• Knowler W. C., Bennett P. M., Ballintine E. J. Increased incidence of retinopathy in diabetics with elevated blood pressure. New England Journal of Medicine 1980; 302: 645–650
   PubMed Web of Science ®Google Scholar
• Chaturvedi N., Sjolie A.-K., Stephenson J. M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepenok Z., Fuller J. H. and the EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28–31
   PubMed Web of Science ®Google Scholar
• Su H. Y., Sheu W. H., Chin H. M., Jeng C. Y., Chen Y. D., Reaven G. M. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. American Journal of Hypertension 1995; 8: 1067–1071
   PubMed Web of Science ®Google Scholar
• Lithell H. O. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. American Journal of Hypertension 1996; 9: 150S–154S
   PubMed Web of Science ®Google Scholar
• Kjekshus J., Gilpin E., Cali G., Blackey A. R., Henning H., Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. European Heart Journal 1990; 11: 43–50
   PubMed Web of Science ®Google Scholar
• Tatti P., Pahor M., Byington R. P., Di Mauro P., Guarisco R., Strollo G., Strollo F. Outcome results of the Fosinopril versus Amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603
   PubMed Web of Science ®Google Scholar
• Estacio R. O., Jeffers B. W., Hiatt W. R., Biggerstaff S. L, Gifford N., Schrier R. W. The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine 1998; 338: 645–652
   PubMed Web of Science ®Google Scholar
• Ruilope L. M., Garcia-Robles R. How far should blood pressure be reduced in diabetic hypertensive patients?. Journal of Hypertension 1997; 15(suppl 2)S63–S65
   Google Scholar
• Lomas J. Words without action? The production dissemination and impact of consensus recommendations. Annual Review of Public Health 1991; 12: 41–65
   PubMed Web of Science ®Google Scholar
• Davis D. A., Thomson M. A., Oxman A. D., Haynes R. B. Evidence for the effectiveness of CME. A review of 50 randomised controlled trials. Journal of the American Medical Association 1992; 268: 1111–1117
   PubMed Web of Science ®Google Scholar
• Oxman A. D., Thomson M. A., Davis D. A., Haynes R. B. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Canadian Medical Asociation Journal 1995; 153: 1423–1431
   PubMed Web of Science ®Google Scholar
• Grol R., Dalhuijsen J., Thomas S., in't Veld C., Rutten G., Mokkink H. Atrributes of clinical guidelines that influence use of guidelines in general practice: observational study. British Medical Journal 1998; 317: 858–861
   PubMed Web of Science ®Google Scholar